CSF2 and rheumatoid arthritis: We emphasize, however, that the safety profile has been favourable during clinical development of GM-CSF blocking antibodies in rheumatoid arthritis, and the current clinical effectiveness data suggest that GM-CSF blockade is a valuable extension of available therapeutic options for inflammatory diseases [10, 11].